On October 13, 2026, Black Hawk Acquisition Corporation filed an 8-K with the SEC, detailing the results of an extraordinary general meeting of shareholders held on the same day. This filing is significant as it outlines critical decisions made by shareholders that could impact the company's future direction and operations.

Background

Black Hawk Acquisition Corp, identified by CIK 0002000775, is a special purpose acquisition company (SPAC) focused on merging with or acquiring businesses in the life sciences sector. The company is incorporated in the Cayman Islands and is listed on the Nasdaq under the trading symbols BKHAU for units, BKHA for ordinary shares, and BKHAR for rights. The Form 8-K is a current report that companies must file with the SEC to announce major events that shareholders should know about.

What the Filing Says

The filing reveals that on October 13, 2026, Black Hawk Acquisition Corp held an extraordinary general meeting where shareholders voted on eight proposals. The record date for eligible shareholders was September 1, 2026, with 4,153,577 ordinary shares outstanding. A quorum was established with 3,211,516 shares, or approximately 77.3%, present either virtually or by proxy.

Among the proposals voted on, the first was the Business Combination Proposal, which was approved by ordinary resolution. This proposal involved a merger with Vesicor Therapeutics, Inc. The voting results were:

For: 3,191,351 Against: 20,165 Abstain: 0

The second proposal, the Domestication Proposal, which aimed to transfer the company from the Cayman Islands to Delaware, also passed with the same voting results:

For: 3,191,351 Against: 20,165 Abstain: 0

The third proposal involved the adoption of new organizational documents, which was similarly approved:

For: 3,191,351 Against: 20,165 Abstain: 0

In addition, shareholders elected five directors to the board following the merger, with each nominee receiving the following votes:

For: 3,191,351 Against: 20,165 Abstain: 0

The Nasdaq Proposal, which involved the issuance of shares post-domestication, was also approved:

For: 3,191,352 Against: 20,164 Abstain: 0

Impact

This filing and the subsequent shareholder approvals are likely to affect various stakeholders, including current and potential investors, employees, and partners of Black Hawk Acquisition Corp and Vesicor Therapeutics. The successful merger could lead to new opportunities for growth and expansion in the life sciences market, particularly as the combined entity seeks to innovate and develop new products.

What's Next

The filing does not specify what happens next, but typically, following such approvals, companies move forward with the execution of the merger and the transition to the new corporate structure in Delaware.